8-K: BioMarin Updates 2025 Revenue, Announces ROCTAVIAN Write-Down

BioMarin Pharmaceutical Inc. provided preliminary 2025 financial estimates, reporting approximately $3.2 billion in total revenues and a significant asset write-down for its ROCTAVIAN gene therapy.

Summary

• Preliminary total revenues for the year ended December 31, 2025, are estimated at approximately $3.2 billion.
• VOXZOGO revenues for the same period are estimated at approximately $920 million.
• An asset write-down related to ROCTAVIAN of approximately $230 million to $260 million is expected in the fourth quarter ended December 31, 2025.
• Approximately $120 million to $125 million of this write-down, or $(0.60) to $(0.64) per share (assuming 200 million weighted-average diluted shares), is expected to reduce Non-GAAP Income and Non-GAAP Diluted EPS for 2025.
• Excluding the ROCTAVIAN write-down, the 2025 full-year financial guidance for Non-GAAP Diluted EPS, previously provided on October 27, 2025, remains unchanged.
• ROCTAVIAN revenue will be excluded from 2026 guidance.
• The company presented this update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While core product revenue (VOXZOGO) is strong and overall revenue is at the high end of guidance, the significant asset write-down for ROCTAVIAN and its exclusion from future guidance is a notable negative. The unchanged Non-GAAP EPS guidance (excluding the write-down) provides some stability, but the write-down itself is a material adverse event. The strategic acquisition plans offer future growth potential but also introduce integration and financing risks.

Positives

• Preliminary total revenues of approximately $3.2 billion for 2025 are at the high end of or exceed the previous guidance range of $3.15 billion to $3.2 billion.
• VOXZOGO revenues of approximately $920 million for 2025 are within the previous guidance range of $900 million to $935 million, indicating continued strong performance for this product.
• Non-GAAP Diluted EPS guidance for 2025, excluding the ROCTAVIAN asset write-down, remains unchanged, suggesting underlying operational performance is in line with expectations.
• The company plans to expand VOXZOGO for achondroplasia and add a second indication for hypochondroplasia in 2027, following pivotal data release in the first half of 2026.
• Expectations for BMN 333's efficacy to potentially set a new standard of treatment for achondroplasia.
• Plans for pipeline expansion through external innovation and continued growth of the Enzyme Therapies portfolio (PALYNZIQ, Galafold, Pombiliti, Opfolda).
• The proposed acquisition of Amicus Therapeutics is expected to accelerate growth, diversify revenue, and be substantially accretive beginning in 2027.

Negatives

• A significant asset write-down related to ROCTAVIAN of approximately $230 million to $260 million is expected in the fourth quarter of 2025.
• This write-down will reduce Non-GAAP Income and Non-GAAP Diluted EPS by approximately $120 million to $125 million, or $(0.60) to $(0.64) per share, for 2025.
• ROCTAVIAN revenue will be excluded from 2026 guidance, indicating a diminished commercial outlook for the product.
• The write-down includes inventory, facilities, intangible assets, and severance costs, suggesting broader operational impacts related to ROCTAVIAN.

Risks

• Actual results may differ materially from preliminary estimated unaudited financial information due to the completion of normal quarterly and annual accounting and financial statement closing procedures.
• Risks and uncertainties related to the timing of orders for commercial products and the company's ability to meet product demand.
• Risks associated with the proposed acquisition of Amicus Therapeutics, including obtaining financing, stockholder approval, competing offers, satisfaction of closing conditions, effects on stock price and operating results, integration challenges, and impacts on relationships with key third parties.
• General risks detailed in BioMarin's filings with the SEC, including those under "Risk Factors" in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Future Outlook

BioMarin expects to report its full 2025 results in February 2026. ROCTAVIAN revenue will be excluded from 2026 guidance, indicating a shift in focus. The company plans significant pipeline expansion, including adding a second indication for hypochondroplasia for VOXZOGO in 2027, following pivotal data in the first half of 2026. BMN 333 is anticipated to set a new standard for achondroplasia treatment. The proposed acquisition of Amicus Therapeutics is expected to accelerate growth, diversify revenue, and become substantially accretive starting in 2027.

Industry Context

This announcement highlights the inherent risks and rewards in the biotechnology and rare disease sectors. While VOXZOGO demonstrates strong commercial success in a specialized market, the significant write-down for ROCTAVIAN underscores the challenges and high costs associated with developing and commercializing gene therapies, particularly in achieving market adoption and sustained revenue. The strategic acquisition of Amicus Therapeutics signals BioMarin's intent to diversify its revenue streams and strengthen its position in rare diseases, a common strategy for growth in this capital-intensive industry.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to the ROCTAVIAN asset write-down and its EPS impact; however, strong VOXZOGO performance and strategic acquisition plans could provide long-term value.
• Employees: Severance costs are included in the ROCTAVIAN write-down, indicating potential job impacts related to that product.
• Customers: Continued availability and expansion of key products like VOXZOGO, PALYNZIQ, Galafold, Pombiliti, and Opfolda.
• Creditors: Potential impact from financing activities related to the Amicus Therapeutics acquisition.

Next Steps

• Report results for the fourth quarter and full year 2025 in February 2026.
• Complete the proposed acquisition of Amicus Therapeutics.
• Release pivotal data with VOXZOGO in hypochondroplasia in the first half of 2026.
• Expand VOXZOGO for achondroplasia and add a second indication for hypochondroplasia in 2027.
• Continue development of BMN 333 for achondroplasia.
• Expand and globally launch Pombiliti and Opfolda.
• Expand Galafold.
• Pursue pipeline expansion through external innovation.

Key Dates

Recommendation

The preliminary results present a mixed picture. Strong revenue performance, particularly from VOXZOGO, is positive, and the core Non-GAAP EPS guidance remains stable when excluding the ROCTAVIAN write-down. However, the substantial ROCTAVIAN asset write-down is a significant negative, indicating challenges with a key gene therapy product and impacting profitability. The proposed acquisition of Amicus Therapeutics offers future growth but also introduces integration and financing risks. Given these offsetting factors, a "hold" recommendation is appropriate until full audited results are released and more clarity emerges regarding the Amicus acquisition and the long-term strategy for the pipeline.

Keywords

BioMarin Pharmaceutical, BMRN, SEC Filing, 8-K, Financial Results, Revenue, VOXZOGO, ROCTAVIAN, Asset Write-Down, Non-GAAP EPS, Biotechnology, Rare Disease, Gene Therapy, Achondroplasia, Hypochondroplasia, Amicus Therapeutics, Acquisition